Protective effect of triclosan in monocrotaline-induced pulmonary arterial hypertension: FASN inhibition a novel approach

Autor: Nimer Alsabeelah, Vinay Kumar

Publikováno v: Journal of Pharmacy and Bioallied Sciences, Vol 14, Iss 4, Pp 171-177 (2022)

Background: Novel pharmacological approaches are needed to improve the outcomes of patients with idiopathic pulmonary hypertension. Fatty acid synthase (FASN) inhibitors have shown beneficial effects in preclinical models of pulmonary arterial hypert

Externí odkaz: https://doaj.org/article/679aa3a65dae4993975be6d0f51dc193

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Abstract P6-11-09: Heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-In-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel

Autor: Peter Schmid, Kathleen N. Moore, Andrew Brenner, Arthur E. Frankel, Gerald Steven Falchook, H. A. Burris, Katharine Grimmer, Juanita Lopez, George Kemble, EM Dean, J. R. Infante, William McCulloch, Erkut Borazanci, Steven J.M. Jones, Manish R. Patel, H.-T. Arkenau

Publikováno v: Cancer Research. 77:P6-11

Introduction FASN inhibition is a novel approach to cancer treatment involving selective disruption of palmitate biosynthesis that, in tumor cells, leads to apoptosis. TVB-2640 is an oral, first-in-class, small molecule reversible inhibitor of FASN t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a44f3b152683468749656b9e0266a0c3
https://doi.org/10.1158/1538-7445.sabcs16-p6-11-09

Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer

Autor: Peter Leonhardt, Agnieszka Morgenroth, K. Bräutigam, Nicolai Maass, Ivo Meinhold-Heerlein, Rene Tolba, Dirk Bauerschlag, Felix M. Mottaghy, Felix Zeppernick, Ulrich Pecks, Frederik A. Verburg

Publikováno v: Journal of Translational Medicine, 13. BioMed Central Ltd
Journal of Translational Medicine
Journal of translational medicine 13(1), 146 (2015). doi:10.1186/s12967-015-0511-3

Background Fatty acid synthase (FASN) is crucial to de novo long-chain fatty acid synthesis, needed to meet cancer cells’ increased demands for membrane, energy, and protein production. Methods We investigated FASN overexpression as a therapeutic a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee199bf02caf4c0ad794ee576f3f848a
https://cris.maastrichtuniversity.nl/en/publications/003d4596-339a-498c-a962-da25854c8d2c

Abstract LB-214: FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study

Autor: Joanna Waszczuk, Marina Fridlib, Doug Buckley, William McCulloch, Richard Crowley, Marie O'Farrell, Claudia Rubio, Katharine Grimmer, Julie Lai, George Kemble, Richard Benn Abegania Ventura, Tim Heuer

Publikováno v: Cancer Research. 76:LB-214

TVB-2640 is an oral, first-in-class, selective and reversible inhibitor of fatty acid synthase (FASN) in Phase 1 testing in solid tumor patients (study 3V2640-CLIN-002). FASN is a central mediator of neoplastic lipogenesis and uniquely catalyzes the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f83057e6e32f27edd75210ae9e587ca2
https://doi.org/10.1158/1538-7445.am2016-lb-214